Oncolytic poliovirus for human tumors
AssigneeDuke University
InventorsMatthias Gromeier, John H. Sampson, Darell D. Bigner, Annick Desjardins, Henry S. Friedman
Life of this patent
Estimating the term…
Abstract
Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.
Claims22
A method of treating a human harboring a glioblastoma tumor which expresses NECL5 (nectin- like protein 5), said method comprising the steps of:
- administering directly to the glioblastoma tumor in the human a chimeric poliovirus construct comprising a Sabin type I strain of poliovirus with a human rhinovirus 2 (HRV2) internal ribosome entry site (IRES) in said poliovirus' 5′ untranslated region between said poliovirus' cloverleaf and said poliovirus' open reading frame.
A method of treating a human harboring a glioblastoma tumor which expresses NECL5 (nectin- like protein 5), said method comprising the steps of:
- testing a glioblastoma tumor to ascertain that it expresses NECL5;
- administering directly to the glioblastoma tumor in the human a chimeric poliovirus construct comprising a Sabin type I strain of poliovirus with a human rhinovirus 2 (HRV2) internal ribosome entry site (IRES) in said poliovirus' 5′ untranslated region between said poliovirus' cloverleaf and said poliovirus' open reading frame, wherein the administering is stereotactically guided, intracerebral infusion with convection enhanced delivery.
A method of delivering a clinical pharmaceutical preparation to a glioblastoma tumor in a human, comprising:
- administering via convection enhanced infusion through a single intratumoral catheter, a dose of a poliovirus construct within 6.5 hours, wherein said poliovirus construct is in a clinical pharmaceutical preparation comprising a Sabin type I strain of poliovirus with a human rhinovirus 2 (HRV2) internal ribosome entry site (IRES) in said poliovirus' 5′ untranslated region between said poliovirus' cloverleaf and said poliovirus' open reading frame;
- and gadolinium.
Dependencies are inferred from the claim text.